Paget’s disease starts with the purposeless proliferation of osteoclasts that destroy bone, thus releasing minerals from the collagenous matrix.\textsuperscript{1,2} Subsequently osteoblast activity increases in an attempt to repair the damage, resulting in new bone formation and elevation of serum alkaline phosphatase (ALP). It is common in persons of Anglo-Saxon origin\textsuperscript{3} but rare in Arabs.\textsuperscript{4,5} The diseased bone tissue becomes vascular.\textsuperscript{6} Newly formed collagen is aligned incorrectly and causes the classical abnormal mosaic pattern; new bone is, therefore, weaker and liable to deformity and fracture.\textsuperscript{1,7}

Bisphosphonate therapy is now the most commonly used treatment for Paget’s disease, often normalizing biochemical markers of the bone turnover for prolonged periods.\textsuperscript{9} Here we report the case of a 66-year-old patient who responded dramatically to treatment with calcitonin followed by a single injection of zoledronic acid.

CASE REPORT

A 66-year-old Omani male presented to the endocrine clinic in Sultan Qaboos University Hospital with a six-year history of progressive skull enlargement [Figure 1], bone pain, left-sided deafness, tinnitus, and unsteadiness of gait. He had undergone coronary artery bypass surgery successfully seven months prior. He was taking simvastatin, aspirin, and valsartan. A magnetic resonance imaging (MRI) brain scan was obtained three months earlier to exclude the possibility of a space-occupying lesion. His physical examination revealed enlargement of the skull and sensory neural deafness in his left ear. The investigations showed normal bone, electrolytes, and liver profiles (calcium 2.3 mmol/L, phosphate

**ARTICLE INFO**

**Article history:**
Received: 20 November 2014
Accepted: 14 February 2015

**Online:**
DOI 10.5001/omj.2016.28

**Keywords:**
Paget’s Disease of Bone; Alkaline Phosphatase; Calcitonin; Zoledronic acid.
1.3 mmol/L, creatinine 80 mmol/L, albumin 48 g/L, aspartate aminotransferase (AST) 25 U/L, and alanine aminotransferase (ALT) 21 U/L. However, he had grossly elevated serum ALP (1500 IU/L; normal range 45–100) and bone formation and resorption markers osteocalcin (139 UG/L; normal range 13–25) and urinary deoxypyridinoline/creatinine (63 nmol/L; normal range 2.3–5.4). The skull X-ray showed thick bones and the "cotton wool" spots that characterize the osteoblastic response [Figure 1]. The bone scan showed the involvement of skull, ribs, cervical spine, and tibia with an isotopic skull:femoral ratio of 34% [Figure 2]. The clinical, biochemical, and radiological findings were diagnostic of active Paget’s disease. The patient was unaware of any similarly affected family member.

Initially, we started him on subcutaneous calcitonin daily for six months. During this time his bone pain improved, and there was a small fall in ALP levels. This was followed by a single 5 mg intravenous injection of zoledronic acid. This resulted in a gradual reduction of serum ALP from 1500 U/L to 112 U/L [Figure 3], and normalization of osteocalcin and urinary deoxypyridinoline levels [Table 1] over an 18 month period with a considerable improvement in his clinical symptoms. There was a reduction in head size, indicated by the size of his Kuma (an Omani hat). A repeat bone scan revealed a marked reduction of the skull:femur ratio from 34% to 4% [Figure 4]. Currently, his response to treatment is

**Table 1: Osteocalcin and urinary deoxypyridinoline levels before and after treatment.**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Osteocalcin</th>
<th>Urinary deoxypyridinoline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before</td>
<td>139</td>
<td>63</td>
</tr>
<tr>
<td>After</td>
<td>28</td>
<td>5</td>
</tr>
</tbody>
</table>

Urinary deoxypyridinoline/creatinine normal range 2.3–5.4 nmol/L. Osteocalcin normal range 13–25 UG/L.

**Figure 1:** The skull X-ray showed thick bones and the "cotton wool" spots that characterize the osteoblastic response.

**Figure 2:** A technetium-99m hydroxy diphosphonate bone scan before treatment showed increased uptake in the affected areas; the skull, spine, pelvis, and the right tibia. Uptake in the skull was high (97%) compared to the left femur (3%) with a ratio of 34%.
being monitored with serial ALP measurement. If these increase, a further infusion of zoledronic acid will be given. He was also given calcium and vitamin D3 two weeks before starting treatment to exclude the possibility of associated vitamin D deficiency osteomalacia.

**DISCUSSION**

Paget’s disease of bone is a localized bone remodeling disorder of uncertain etiology, although environmental and genetic factors are thought to be involved. In the UK, mutations of the sequestosome 1 gene (SQSTM1) are found in approximately 11% of affected individuals. Patients with mutations present at an earlier age and have more affected bones than those without mutations. Currently, the American Society for Bone and Mineral Research do not recommend routine genetic testing. Paget’s disease is not new and was found in 1000-year-old Anglo-Saxon skeletal remains. Both men and women are affected with slight male preponderance. The bone that is remodeled by this pathological process becomes enlarged and mechanically weakened. A stretched periosteum produces bone pain by enlargement of the bone or by increased pressure on the medulla due to increased blood flow in the diseased bone. This bone expansion will cause skeletal deformity, fractures, and various neurological compression syndromes. However, most patients with Paget’s disease are asymptomatic and discovered because of increased serum ALP or as an incidental X-ray finding.

This disorder is most unusual in the Arab world, which explains why the diagnosis is often delayed. Affected individuals are often thought to have bone tumors or osteomyelitis. We elected to treat this patient due to the presence of the following: bone pain, extensive skull involvement, tinnitus, and unsteadiness of gait. Prophylactic treatment may be
indicated in several situations including preparation for orthopedic procedures and vertebral body involvement to prevent neurologic compression syndromes.\textsuperscript{14}

The patient was started on calcitonin initially as this drug directly inhibits osteoclast activity and reduces bone pain, which is possibly due to the fall in bone blood flow.\textsuperscript{15,16} Using calcitonin for three to six months before giving the patient bisphosphonate will allow bone remodeling and normal lamellar bone formation.\textsuperscript{17,18}

A good example of this was seen in a treated Saudi Bedouin patient, where healing of the V-shaped bony defects and the cortical bone remodeling during treatment with calcitonin occurred.\textsuperscript{4} The use of bisphosphonates alone can produce healing of lytic lesions on radiographs, but they do not induce bone remodeling.\textsuperscript{19}

Calcitonin treatment is infrequently used in the treatment of Paget’s disease. However, our experience indicates that it will improve bone remodeling with obvious radiological improvement in juvenile\textsuperscript{20} and adult Paget’s disease.\textsuperscript{4} Furthermore, normal lamellar bone is laid down during treatment.\textsuperscript{18} For this reason, we usually give a short course of calcitonin before starting bisphosphonate treatment particularly when affected areas of the bone are likely to cause problems and need strengthening.

After six months of calcitonin treatment to achieve cortical bone healing, the patient received a 5 mg intravenous infusion of zoledronic acid. There was further progressive clinical and biochemical improvement and after one year his serum ALP and bone turnover markers became normal. This effect has persisted for 3 years, to date. Zoledronic acid was chosen as it proved to be more effective in Paget’s disease than the other available bisphosphonates.\textsuperscript{19}

**CONCLUSION**

Patients with Paget’s disease requiring treatment should receive calcitonin initially to reduce bone turnover and allow normal bone remodeling before starting treatment with a bisphosphonate.

**Disclosure**

The authors declared no conflicts of interest.

**REFERENCES**